Sironax
Latest round
- Series B
Last raised
- Aug 2022
Total raised
- $200M
Investors
- 15
About Sironax
Established in 2017 and based in Beijing, China, Sironax Ltd. is a biotechnology company focused on developing new therapies for patients with degenerative diseases of the elderly. The company operates in China and the United States and has approximately 180 employees. Previously, the company completed nominations, healthy subjects and patient studies for its lead development drug SIR0365 by 2020, and opened a second Ph1b study in 2021. The company's chairman and co-founder, Dr.S. National Academy of Sciences since 2004 and a foreign member of the Chinese Academy of Sciences since 2013, and also co-founded Baji Shenzhou. Sironax focuses on the development and production of inhibitors, with a research pipeline consisting of multiple programs targeting the regulation of cell death, neuroprotective pathways and neuroinflammation. The pipeline contains seven innovative programs spanning small and large molecules, with the main RIPK1 program consisting of several chemically differentiated small molecule inhibitors, including SIR0365 and SIR2446.
Who invested in Sironax
15 investors across 1 round
See all investors in Sironax
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
Aug 2, 2022
Amount
$200M
Investors
Questions about Sironax
Who invested in Sironax?
Sironax has 15 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Sironax raised?
Sironax has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Sironax last raise money?
Sironax's most recent round on record is a Series B, in Aug 2022.
What does Sironax do?
Established in 2017 and based in Beijing, China, Sironax Ltd.
Where is Sironax headquartered?
Sironax is headquartered in Beijing, China.
Which VCs invest in companies like Sironax?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Sironax's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Sironax? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.